Physician profile
Robin Starr
NPI 1053384537
$3,446.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,104 · 2022: $1,342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $636.65 | 2021-2022 | |
| Abbvie INC. | $565.81 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $360.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $282.35 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.94 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $207.84 | 2021-2022 | |
| Eisai INC. | $193.97 | 2021-2022 | |
| Alkermes, INC. | $154.82 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $130.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $118.51 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $102.09 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $88.69 | 2021-2022 | |
| Lundbeck LLC | $87.74 | 2021-2022 | |
| Bausch Health US, LLC | $78.41 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $50.04 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $42.06 | 2021 | |
| Neos Therapeutics, LP | $37.40 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $21.28 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.27 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.